Scholarlink

Background <p>Bleomycin, etoposide, and platinum (BEP) are among the most commonly used and effective anticancer medications in oncology clinics. The study’s objective was to examine the efficacy of curcumin and curcumin-cyclodextrin (nanocurcumin) as protective agents against BEP nephrotoxicity.</p> Methods <p>Renal toxicity was evaluated through various parameters, such as histopathology and serum urea and creatinine levels. In addition, the levels of Nitric Oxide (NO) and total antioxidant capacity (TAC) and the expression of the Tumor Necrosis Factor-alpha (TNF-α) and caspase 3 genes were investigated. These experiments were performed on Wistar rats, which were divided into six groups: control, BEP, curcumin, nanocurcumin, curcumin + BEP, and nanocurcumin + BEP.</p> Results <p>The findings of the present study revealed that the administration of curcumin and nanocurcumin improved the blood urea and creatinine levels and improved kidney histology in rats treated with BEP. In addition, curcumin and nanocurcumin strengthened the antioxidant status in the kidney by increasing TAC and decreasing NO levels. Therefore, alterations in the gene expression of TNF-α and caspase3 showed that curcumin could modulate and regulate the process of apoptosis and inflammation caused by BEP.</p> Conclusions <p>These results showed that curcumin protects kidneys from BEP-induced toxicity by reducing oxidative stress, cell death, and inflammation, and it can be considered a possible option to improve renal complications caused by the BEP chemotherapy regimen.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The protective effect of curcumin nanoparticles on renal damage caused by a combination of bleomycin, etoposide, and cisplatin

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月5日

查看全文
  • Zohreh Bartani,
  • Houshang Nemati,
  • Saber Heshmati,
  • Mitra Tarlan,
  • Masoud Sadeghi

摘要

Background

Bleomycin, etoposide, and platinum (BEP) are among the most commonly used and effective anticancer medications in oncology clinics. The study’s objective was to examine the efficacy of curcumin and curcumin-cyclodextrin (nanocurcumin) as protective agents against BEP nephrotoxicity.

Methods

Renal toxicity was evaluated through various parameters, such as histopathology and serum urea and creatinine levels. In addition, the levels of Nitric Oxide (NO) and total antioxidant capacity (TAC) and the expression of the Tumor Necrosis Factor-alpha (TNF-α) and caspase 3 genes were investigated. These experiments were performed on Wistar rats, which were divided into six groups: control, BEP, curcumin, nanocurcumin, curcumin + BEP, and nanocurcumin + BEP.

Results

The findings of the present study revealed that the administration of curcumin and nanocurcumin improved the blood urea and creatinine levels and improved kidney histology in rats treated with BEP. In addition, curcumin and nanocurcumin strengthened the antioxidant status in the kidney by increasing TAC and decreasing NO levels. Therefore, alterations in the gene expression of TNF-α and caspase3 showed that curcumin could modulate and regulate the process of apoptosis and inflammation caused by BEP.

Conclusions

These results showed that curcumin protects kidneys from BEP-induced toxicity by reducing oxidative stress, cell death, and inflammation, and it can be considered a possible option to improve renal complications caused by the BEP chemotherapy regimen.

Clinical trial number

Not applicable.